Clinical trial
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
NCT00010192 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00010192 |
|---|---|
| Title | Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer |
| Official title | A Phase I Trial Of Rituximab And Interleukin-2 |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma and 43 more |
| Intervention type | Biological, Other |
| Interventions | rituximab, aldesleukin, laboratory biomarker analysis, pharmacological study |
| Enrollment | 30 |
| Start date | Dec 1, 2000 |
| Primary completion | Jan 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: